Previous 10 | Next 10 |
NOVATO, Calif., May 18, 2021 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, today reported the grant of non-qualified stock options to purcha...
Ultragenyx Pharmaceutical (RARE) announces positive longer-term data from the Glycogen Storage Disease Type Ia (GSDIa) and Ornithine Transcarbamylase ((OTC)) Deficiency Phase 1/2 studies demonstrating ongoing durability of response, as well as data highlighting further advancements to the com...
Durable and Clinically Meaningful Responses Maintained at More than 2.5 and 3 Years Post-Treatment in Phase 1/2 Studies of DTX401 for GSDIa and DTX301 for OTC Next-Generation HeLa Producer Cell Line Manufacturing Platform Results in Significant Product Yield Increases NOVATO...
A powerful biotech company can undergo strong fundamentals development and yet its stock doesn't appreciate much at all. Regenxbio's licensee asset (Zolgensma) is delivering blockbuster results. The crowned jewel (RGX-314) and other pipeline medicine are poised to generate positive cl...
NOVATO, Calif., May 10, 2021 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced that Mardi Dier, the company's Ch...
Kyowa Kirin (KYKOF) announced that the European Medicines Agency ((EMA)) has recommended the self-administration option of CRYSVITA (burosumab) for the treatment of X-linked hypophosphataemia ((XLH)).The decision by the Committee for Medicinal Products for Human Use ((CHMP)) of EMA ...
Are These Top Health Care Stocks Still A Good Investment Right Now? As an investor in the stock market , health care stocks are always enticing. After all, medical care is a necessity for everyone at some point. This could range from the usage of drugs, surgeries, and even medic...
The following slide deck was published by Ultragenyx Pharmaceutical Inc. in conjunction with their 2021 Q1 earnings call. For further details see: Ultragenyx Pharmaceutical Inc. 2021 Q1 - Results - Earnings Call Presentation
Esperion sheds nearly a third on Stifel cut Esperion Therapeutics (ESPR) has lost ~32.8% in the early hours after Stifel downgraded the stock to hold from buy noting “we don't think this story gets any better soon.”Esperion’s Q1 2021 financials came be...
Image source: The Motley Fool. Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) Q1 2021 Earnings Call May 4, 2021 , 5:00 p.m. ET Operator Continue reading For further details see: Ultragenyx Pharmaceutical Inc (RARE) Q1 2021 Earnings Call Tra...
News, Short Squeeze, Breakout and More Instantly...
Ultragenyx Pharmaceutical Inc. Company Name:
RARE Stock Symbol:
NASDAQ Market:
Ultragenyx Pharmaceutical Inc. Website:
NOVATO, Calif., July 25, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultrarare genetic diseases, today announced that it will host a conference call at 5...
NOVATO, Calif., July 24, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that the company will share the latest clinical data, regulatory progress and program next steps for GTX-102, its investigational antisense oligonucleotide for Angelman syndrome, on Wed...
2024-07-24 04:06:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...